Matrix metalloproteinases as drug targets in Preeclampsia

Current Drug Targets

Volumn 14, Issue 3, 2013, Pages 325-334

  Palei, Ana C T ^a   Granger, Joey P ^a   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Hypertensive disorders; Matrix metalloproteinases; Preeclampsia; Pregnancy; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CHORIONIC GONADOTROPIN; DOXYCYCLINE; ENDOTHELIN A RECEPTOR; ESTROGEN; GELATINASE A; GELATINASE B; HYDRALAZINE; HYPERTENSIVE FACTOR; LABETALOL; LERCANIDIPINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLDOPA; NIFEDIPINE; NIMODIPINE; PEROXYNITRITE; PROGESTERONE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; BIOAVAILABILITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FETUS DISEASE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; ISCHEMIA; KIDNEY BLOOD FLOW; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERFUSION PRESSURE; PLACENTA PERFUSION; PREECLAMPSIA; PREGNANCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TERATOGENICITY; TROPHOBLAST; VASOCONSTRICTION;

EID: 84876714906     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804999034     Document Type: Review

References (165)

1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of preeclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25: 391-403.
2. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-74.
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
4. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003; 41: 437-45.
5. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Bmj 2007; 335: 974.
6. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-30.
7. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800-9.
8. Davis EF, Lazdam M, Lewandowski AJ, et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012; 129: e1552-61.
9. Broughton Pipkin F. Risk factors for preeclampsia. N Engl J Med 2001; 344: 925-6.
10. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Bmj 2005; 330: 565.
11. Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: Risk factors and causal models. Best Pract Res Clin Obstet Gynaecol 2011; 25: 329-42.
12. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens 2008; 2: 484-94.
13. VanWijk MJ, Kublickiene K, Boer K, VanBavel E. Vascular function in preeclampsia. Cardiovasc Res 2000; 47: 38-48.
14. Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54: 2056-63.
15. Clapp JF, 3rd, Capeless E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol 1997; 80: 1469-73.
16. Pirani BB, Campbell DM, MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw 1973; 80: 884-7.
17. Scott DE. Anemia in pregnancy. Obstet Gynecol Annu 1972; 1: 219-44.
18. Taylor DJ, Lind T. Red cell mass during and after normal pregnancy. Br J Obstet Gynaecol 1979; 86: 364-70.
19. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256: H1060-5.
20. Flo K, Wilsgaard T, Vartun A, Acharya G. A longitudinal study of the relationship between maternal cardiac output measured by impedance cardiography and uterine artery blood flow in the second half of pregnancy. Bjog 2010; 117: 837-44.
21. Jurkovic D, Jauniaux E, Kurjak A, Hustin J, Campbell S, Nicolaides KH. Transvaginal color Doppler assessment of the uteroplacental circulation in early pregnancy. Obstet Gynecol 1991; 77: 365-9.
22. Thaler I, Manor D, Itskovitz J, Rottem S, et al. Changes in uterine blood flow during human pregnancy. Am J Obstet Gynecol 1990; 162: 121-5.
23. Davison JM. Kidney function in pregnant women. Am J Kidney Dis. 1987; 9: 248-52.
24. Grindheim G, Estensen ME, Langesaeter E, Rosseland LA, Toska K. Changes in blood pressure during healthy pregnancy: a longitudinal cohort study. J Hypertens 2012; 30: 342-50.
25. Mone SM, Sanders SP, Colan SD. Control mechanisms for physiological hypertrophy of pregnancy. Circulation 1996; 94: 667-72.
26. Valensise H, Novelli GP, Vasapollo B, et al. Maternal cardiac systolic and diastolic function: relationship with uteroplacental resistances. A Doppler and echocardiographic longitudinal study. Ultrasound Obstet Gynecol 2000; 15: 487-97.
27. Ganzevoort W, Rep A, Bonsel GJ, de Vries JI, Wolf H. Plasma volume and blood pressure regulation in hypertensive pregnancy. J Hypertens 2004; 22: 1235-42.
28. Longo LD. Maternal blood volume and cardiac output during pregnancy: a hypothesis of endocrinologic control. Am J Physiol 1983; 245: R720-9.
29. Oelkers WK. Effects of estrogens and progestogens on the reninaldosterone system and blood pressure. Steroids 1996; 61: 166-71.
30. Weiner CP, Thompson LP. Nitric oxide and pregnancy. Semin Perinatol 1997; 21: 367-80.
31. Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272: H748-52.
32. Conrad KP, Joffe GM, Kruszyna H, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J 1993; 7: 566-71.
33. Goodman RP, Killam AP, Brash AR, Branch RA. Prostacyclin production during pregnancy: comparison of production during normal pregnancy and pregnancy complicated by hypertension. Am J Obstet Gynecol 1982; 142: 817-22.
34. Greer IA, Walker JJ, McLaren M, et al. Immunoreactive prostacyclin and thromboxane metabolites in normal pregnancy and the puerperium. Br J Obstet Gynaecol 1985; 92: 581-5.
35. Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham J. Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol 2009; 7: 79.
36. Gant NF, Worley RJ, Everett RB, MacDonald PC. Control of vascular responsiveness during human pregnancy. Kidney Int 1980; 18: 253-8.
37. Daniels CR, Eisen V, Slater JD. The renin-angiotensinogen reaction during pregnancy and oral contraception: estimation of kinetic parameters by an autologous plasma renin assay. J Endocrinol 1987; 112: 465-72.
38. Sealey JE, Itskovitz-Eldor J, Rubattu S, et al. Estradiol-and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 1994; 79: 258-64.
39. Valdes G, Germain AM, Corthorn J, et al. Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 2001; 16: 117-22.
40. Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig 2004; 11: 438-48.
41. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94: 978-84.
42. Rang S, Wolf H, van Montfrans GA, Karemaker JM. Serial assessment of cardiovascular control shows early signs of developing pre-eclampsia. J Hypertens 2004; 22: 369-76.
43. Salas SP, Marshall G, Gutierrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006; 47: 203-8.
44. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/ hypoxia with microvascular dysfunction. Microcirculation 2002; 9: 147-60.
45. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2: 543-9.
46. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-9.
47. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499-506.
48. Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178: 5949-56.
49. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension 2006; 48: 711-6.
50. LaMarca B, Speed J, Fournier L, et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension 2008; 52: 1161-7.
51. LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008; 51: 982-8.
52. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009; 54: 905-9.
53. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension 2008; 52: 1168-72.
54. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-52.
55. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46: 1077-85.
56. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
57. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
58. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008; 75: 1-8.
59. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142-7.
60. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55: 394-8.
61. Bridges JP, Gilbert JS, Colson D, et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009; 22: 564-8.
62. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008; 294: H541-50.
63. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004; 11: 342-52.
64. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999; 33: 83-9.
65. Walsh SW. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol 1998; 16: 93-104.
66. Sedeek M, Gilbert JS, LaMarca BB, et al. Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. Am J Hypertens 2008; 21: 1152-6.
67. LaMarca BD, Alexander BT, Gilbert JS, et al. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? Gend Med 2008; 5 Suppl A: S133-8.
68. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71: 1675-7.
69. Benigni A, Orisio S, Gaspari F, Frusca T, Amuso G, Remuzzi G. Evidence against a pathogenetic role for endothelin in preeclampsia. Br J Obstet Gynaecol 1992; 99: 798-802.
70. Damsky CH, Fitzgerald ML, Fisher SJ. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. J Clin Invest 1992; 89: 210-22.
71. Damsky CH, Librach C, Lim KH, et al. Integrin switching regulates normal trophoblast invasion. Development 1994; 120: 3657-66.
72. Fisher SJ, Damsky CH. Human cytotrophoblast invasion. Semin Cell Biol. 1993; 4: 183-8.
73. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177-91.
74. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669-74.
75. Pridjian G, Puschett JB. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002; 57: 598-618.
76. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 2006; 312: 608-22.
77. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14: 2123-33.
78. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
79. Isaka K, Usuda S, Ito H, et al. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003; 24: 53-64.
80. Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 1994; 171: 832-8.
81. Lalu MM, Xu H, Davidge ST. Matrix metalloproteinases: control of vascular function and their potential role in preeclampsia. Front Biosci 2007; 12: 2484-93.
82. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006; 8: 1-20.
83. Karthikeyan VJ, Lane DA, Beevers DG, Lip GY, Blann AD. Matrix metalloproteinases and their tissue inhibitors in hypertensionrelated pregnancy complications. J Hum Hypertens 2013; 27(2): 72-8.
84. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152: 189-205.
85. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011; 278: 28-45.
86. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003; 21: 1627-30.
87. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-98.
88. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549-58.
89. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
90. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-94.
91. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-6.
92. Shimajiri S, Arima N, Tanimoto A, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999; 455: 70-4.
93. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005; 45: 258-63.
94. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4: 700-8.
95. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. [Pre-eclampsia: a disorders of the endothelial cells?]. Gynakologe 1992; 25: 2-6.
96. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000; 87: 670-6.
97. Martinez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004; 383: 413-8.
98. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-11.
99. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J 2001; 15: 2230-40.
100. Gearing AJ, Beckett P, Christodoulou M, et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 1995; 57: 774-7.
101. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997; 72: 155-61.
102. Vaday GG, Franitza S, Schor H, et al. Combinatorial signals by inflammatory cytokines and chemokines mediate leukocyte interactions with extracellular matrix. J Leukoc Biol 2001; 69: 885-92.
103. Bischof P, Meisser A, Campana A. Mechanisms of endometrial control of trophoblast invasion. J Reprod Fertil Suppl 2000; 55: 65-71.
104. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol 2005; 3: 56.
105. Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schonbein GW. Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 299: H25-35.
106. Schmid-Schonbein GW. Matrix metalloproteinases activities in hypertension: emerging opportunities. Hypertension 2011; 57: 24-5.
107. Tran ED, DeLano FA, Schmid-Schonbein GW. Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res 2010; 47: 423-31.
108. Tran ED, Yang M, Chen A, Delano FA, Murfee WL, Schmid-Schonbein GW. Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery. Microcirculation 2011; 18: 228-37.
109. Wu KI, Schmid-Schonbein GW. Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011; 57: 261-8.
110. Huisman MA, Timmer A, Zeinstra M, et al. Matrixmetalloproteinase activity in first trimester placental bed biopsies in further complicated and uncomplicated pregnancies. Placenta 2004; 25: 253-8.
111. Kolben M, Lopens A, Blaser J, et al. Proteases and their inhibitors are indicative in gestational disease. Eur J Obstet Gynecol Reprod Biol 1996; 68: 59-65.
112. Shokry M, Omran OM, Hassan HI, Elsedfy GO, Hussein MR. Expression of matrix metalloproteinases 2 and 9 in human trophoblasts of normal and preeclamptic placentas: preliminary findings. Exp Mol Pathol 2009; 87: 219-25.
113. Romanowicz L, Galewska Z. Extracellular Matrix Remodeling of the Umbilical Cord in Pre-eclampsia as a Risk Factor for Fetal Hypertension. J Pregnancy 2011; 2011: 542695.
114. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Gelatinase matrix metalloproteinase (MMP)-2 and MMP-9 of the umbilical cord blood in preeclampsia. Clin Chem Lab Med 2008; 46: 517-22.
115. Lavee M, Goldman S, Daniel-Spiegel E, Shalev E. Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Reprod Biol Endocrinol 2009; 7: 85.
116. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875-80.
117. Palei AC, Sandrim VC, Amaral LM, et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 2011.
118. Montagnana M, Lippi G, Albiero A, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and preeclamptic pregnancy. J Clin Lab Anal 2009; 23: 88-92.
119. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 2005; 24: 103-15.
120. Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenat Diagn 2009; 29: 553-9.
121. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 2001; 20: 185-94.
122. Palei AC, Sandrim VC, Amaral LM, et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 2012; 92: 217-21.
123. Coolman M, de Maat M, Van Heerde WL, et al. Matrix metalloproteinase-9 gene-1562C/T polymorphism mitigates preeclampsia. Placenta 2007; 28: 709-13.
124. Fraser R, Walker JJ, Ekbote UV, Martin KL, McShane P, Orsi NM. Interleukin-4-590 (C>T), toll-like receptor-2 +2258 (G>A) and matrix metalloproteinase-9-1562 (C>T) polymorphisms in preeclampsia. Bjog. 2008; 115: 1052-6; discussion 6.
125. Palei AC, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta. 2010; 411: 874-7.
126. Palei AC, Sandrim VC, Amaral LM, et al. Effects of Matrix Metalloproteinase (MMP)-2 Polymorphisms on Responsiveness to Antihypertensive Therapy of Women with Hypertensive Disorders of Pregnancy. Basic Clin Pharmacol Toxicol 2012.
127. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51: 960-9.
128. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart 2004; 90: 1499-504.
129. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-31.
130. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194-201.
131. Rizzi E, Castro MM, Prado CM, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599-608.
132. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension. 2005; 45: 432-7.
133. Wang M, Zhang J, Telljohann R, et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension 2012; 60: 459-66.
134. Verlohren S, Geusens N, Morton J, et al. Inhibition of trophoblastinduced spiral artery remodeling reduces placental perfusion in rat pregnancy. Hypertension 2010; 56: 304-10.
135. Claussen U, Breuer HW. The teratogenic effects in rabbits of doxycycline, dissolved in polyvinylpyrrolidone, injected into the yolk sac. Teratology 1975; 12: 297-301.
136. Rechtman MP, Zhang J, Salamonsen LA. Effect of inhibition of matrix metalloproteinases on endometrial decidualization and implantation in mated rats. J Reprod Fertil 1999; 117: 169-77.
137. Siddiqui MA, Janjua MZ. Effect of prenatal doxycycline administration on skeletal differentiation in long bones of Albino rat. J Pak Med Assoc 2002; 52: 211-4.
138. Younis HS, Jessen BA, Wu EY, Stevens GJ. Inhibiting matrix metalloproteinases with prinomastat produces abnormalities in fetal growth and development in rats. Birth Defects Res B Dev Reprod Toxicol 2006; 77: 95-103.
139. Bastianini L, Felisati D. [Studies on gravidic and fetal toxicity of alpha-6-deoxy-5-oxytetracycline (doxycycline) in mouse and rabbit]. Antibiotica 1970; 8: 161-78.
140. Cahen RL, Fave A. Absence of teratogenic effect of 6-alphadeoxy-5 oxytetracycline. Fed Proc Fed Am Soc Exp Biol 1972: 238.
141. Delahunt CS, Jacobs RT, Stebbins RB, Reiser N. Toxicology of vibramycin. Toxicol Appl Pharmacol 1967: 402.
142. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012; 103: 209-79.
143. Schwarz EB, Maselli J, Norton M, Gonzales R. Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005; 118: 1240-9.
144. Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997; 89: 524-8.
145. Horne HW, Jr., Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil 1980; 25: 315-7.
146. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006; 107: 1120-38.
147. Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dosedependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011; 108: 318-25.
148. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012; 413: 656-62.
149. Zervoudaki A, Economou E, Pitsavos C, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension. Am J Hypertens 2004; 17: 273-6.
150. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-24.
151. Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006; 47: 117-22.
152. Marcal DM, Rizzi E, Martins-Oliveira A, et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 35-44.
153. Martinez ML, Castro MM, Rizzi E, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008; 591: 224-30.
154. Yamada T, Nagata K, Cheng XW, et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009; 615: 163-70.
155. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-8.
156. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007: CD004659.
157. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 2009; 31: 818-26.
158. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-14.
159. Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin--a systematic review and meta-analysis of the main randomized controlled trials. Clinics (Sao Paulo) 2005; 60: 407-14.
160. Lu L, Liu H, Peng J, et al. Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. Lipids Health Dis 2010; 9: 16.
161. Yiqin Y, Meilin X, Jie X, Keping Z. Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. Inflammation 2009; 32: 233-41.
162. Hua Y, Xue J, Sun F, Zhu L, Xie M. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDLstimulated macrophages derived from human monocytes. Pharmacology 2009; 83: 18-25.
163. Nicolae M, Tircol M, Alexandru D. Inhibitory effect of acetylsalicylic acid on matrix metalloproteinase-2 activity in human endothelial cells exposed to high glucose. J Cell Mol Med 2005; 9: 953-60.
164. Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 2011; 64: 551-60.
165. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011; 64: 567-72.